Absence of liver tumor-initiating activity of kojic acid in mice

Mitsuyoshi Moto,Taeko Mori,M. Okamura,Y. Kashida,K. Mitsumori

DOI: https://doi.org/10.1007/s00204-005-0034-4

2006-05-01

Archives of Toxicology

Abstract:

What problem does this paper attempt to address?

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

Peter Nash,Andreas Kerschbaumer,Thomas Dörner,Maxime Dougados,Roy M Fleischmann,Klaus Geissler,Iain McInnes,Janet E Pope,Désirée van der Heijde,Michaela Stoffer-Marx,Tsutomu Takeuchi,Michael Trauner,Kevin L Winthrop,Maarten de Wit,Daniel Aletaha,Xenofon Baraliakos,Wolf-Henning Boehncke,Paul Emery,John D Isaacs,Joel Kremer,Eun Bong Lee,Walter P Maksymowych,Marieke Voshaar,Lai-Shan Tam,Yoshiya Tanaka,Filip van den Bosch,René Westhovens,Ricardo Xavier,Josef S Smolen

DOI: https://doi.org/10.1136/annrheumdis-2020-218398

IF: 27.973

2020-11-06

Annals of the Rheumatic Diseases

Abstract:Objectives Janus kinase inhibitors (JAKi) have been approved for use in various immune-mediated inflammatory diseases. With five agents licensed, it was timely to summarise the current understanding of JAKi use based on a systematic literature review (SLR) on efficacy and safety. Methods Existing data were evaluated by a steering committee and subsequently reviewed by a 29 person expert committee leading to the formulation of a consensus statement that may assist the clinicians, patients and other stakeholders once the decision is made to commence a JAKi. The committee included patients, rheumatologists, a gastroenterologist, a haematologist, a dermatologist, an infectious disease specialist and a health professional. The SLR informed the Task Force on controlled and open clinical trials, registry data, phase 4 trials and meta-analyses. In addition, approval of new compounds by, and warnings from regulators that were issued after the end of the SLR search date were taken into consideration. Results The Task Force agreed on and developed four general principles and a total of 26 points for consideration which were grouped into six areas addressing indications, treatment dose and comedication, contraindications, pretreatment screening and risks, laboratory and clinical follow-up examinations, and adverse events. Levels of evidence and strengths of recommendations were determined based on the SLR and levels of agreement were voted on for every point, reaching a range between 8.8 and 9.9 on a 10-point scale. Conclusion The consensus provides an assessment of evidence for efficacy and safety of an important therapeutic class with guidance on issues of practical management.

rheumatology
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician

Zoltán Szekanecz,Maya H. Buch,Christina Charles-Schoeman,James Galloway,George A. Karpouzas,Lars Erik Kristensen,Steven R. Ytterberg,Attila Hamar,Roy Fleischmann

DOI: https://doi.org/10.1038/s41584-023-01062-9

IF: 32.286

2024-01-13

Nature Reviews Rheumatology

Abstract:Janus kinase (JAK) inhibitors, including tofacitinib, baricitinib, upadacitinib and filgotinib, are increasingly used in the treatment of rheumatoid arthritis (RA). There has been debate about their safety, particularly following the issuance of guidance by regulatory agencies advising caution in their use in certain patients. The registrational clinical trials and registry data of JAK inhibitors did not identify a difference in the risk of major adverse cardiovascular events (MACEs), venous thromboembolism, malignancies or infections (other than herpes zoster) with a JAK inhibitor versus a biologic DMARD. In the ORAL Surveillance trial, which enrolled patients >50 years of age with ≥1 cardiovascular risk factor, tofacitinib was statistically inferior to TNF inhibitors for the occurrence of MACEs and malignancy. Further post hoc analysis of the data revealed that an age of ≥65 years, a high baseline cardiovascular risk, a history of smoking, sustained inflammation, disease activity and suboptimal treatment of cardiovascular comorbidities all increase the risk of these outcomes. The guidance issued by regulatory agencies should be carefully considered to ensure appropriate and safe treatment of patients with RA without undertreatment of patients who might benefit from JAK inhibitor, as well as biologic, treatment. As always, the risks associated with the use of these agents, treatment goals, costs and patient preferences should be discussed with the patient.

rheumatology
Gammarus lacustris harboring Polymorphus paradoxus show altered patterns of serotonin-like immunoreactivity.

B. Maynard,L. Demartini,W. G. Wright

DOI: https://doi.org/10.2307/3283801

1996-08-01

Journal of Parasitology

Abstract:The pattern of serotonin-like immunoreactivity in the central nervous system of individuals of the amphipod Gammarus lacustris harboring polymorphid cystacanths was compared to the pattern seen in individuals not infected with acanthocephalans. Ventral nerve cords from both parasitized and nonparasitized amphipods showed the same bilateral pair of immunoreactive cell bodies in the third thoracic ganglion. Significant differences were noted in the fine structure of these cell bodies, with nerve cords from Polymorphus paradoxus-parasitized amphipods showing a greater number of bright spots or localized points of storage of serotonin. The results of this study indicate that infection of G. lacustris by cystacanths of P. paradoxus, but not P. marilis, is correlated with changes in the anatomy of the serotonergic neurons of the amphipod's central nervous system.
Creating Trust in an Acute Psychiatric Ward

Marit Helene Hem,K. Heggen,K. Ruyter

DOI: https://doi.org/10.1177/0969733008090525

IF: 3.344

2008-11-01

Nursing Ethics

Abstract:The ideal of trust pervades nursing. This article uses empirical material from acute psychiatry that reveals that it is distrust rather than trust that is prevalent in this field. Our data analyses show how distrust is expressed in the therapeutic environment and in the relationship between nurse and patient. We point out how trust can nonetheless be created in an environment that is characterized by distrust. Both trust and distrust are exposed as `fragile' phenomena that can easily `tip over' towards their opposites. Trust is not something that nurses possess or are given; it is rather something that they earn and have to work hard to achieve. Regarding themselves as potential causes of distrust and active wielders of power can contribute to nurses developing a more realistic view of their practice. Assuming a realistic middle-way perspective can help to manoeuvre between the extremities of excellence and resignation, which in turn can lead to processes that create trust between psychotic patients and nurses.
P008 High response rate to Janus Kinase inhibitors after multiple biologic drug failures, across disease indications, in a District General Hospital: results from an audit of the prescribing, safety and efficacy of Janus Kinase inhibitor

Alexa Escudero,Sugandh Jain,Nwe Nisoe,Jeremy McNally,Habib Wardak

DOI: https://doi.org/10.1093/rheumatology/keae163.050

2024-04-01

Rheumatology

Abstract:Abstract Background/Aims This audit aimed to improve the standard of prescribing JAK inhibitors and to determine the sustainability of response in Rheumatology patients at Royal Berkshire hospital (RBH) in Reading. During the last decade Janus kinase (JAK) inhibitors have had a dramatic uptake across multiple conditions in Rheumatology to control inflammation, reduce damage, pain and fatigue. Emerging data provides insight into their safety and effectiveness. These medications are contraindicated in patients with serious infections, cancer, blood clots, pregnancy and abnormal liver or renal function. Prescribing these medications needs careful consideration. We want to ensure we are taking appropriate precautions to minimize them and to review their efficacy in a real world District General Hospital setting. Methods Data was collected retrospectively from 100 patients who started treatment with JAK inhibitors in the last five years. We reviewed the indication, stage of disease, risk factors, whether patient information was provided and the response to treatment. We included patients with Rheumatoid arthritis (RA), Ankylosing Spondylitis, Psoriatic Arthritis. Our data collection template covered demographic information, medical history and disease activity at baseline as well as after starting JAK inhibitors; concomitant use of other DMARDs, safety and efficacy. Results A cohort of 100 patients (69 female and 31 male, average age 51.4 years) diagnosed with rheumatic conditions. The largest group were started on Baricitinib 64%, the smallest group on Upadacitinib. Baricitinib was the first JAK inhibitor approved for use in Rheumatology. Most RA patients were seropositive and had active disease at baseline. Comorbidities such as hypertension and diabetes were noted in 24 % and 14% of the patients respectively. 31% had a past history of smoking history, 9% had a history of malignancy. 22% of patients were on JAK monotherapy, the majority required an additional disease modifying antirheumatic drug (DMARDs). 43% of patients had tried two to three different biologics before starting JAK inhibitors. The average time from diagnosis to the first use of JAK inhibitors was 11 years. 2% of patients developed MACE and 3% herpes zoster on JAK. Only one of the deceased patients was on JAK inhibitors at the time of death and no causality was found. In < 10% of patients discussion on potential side effects was documented at baseline. 36% have discontinued the medication. Conclusion JAK inhibitors are highly effective in a real world population even when started after two to three biologic failures. A significant reduction in disease activity and sustainable remission was obtained in 64% of our patients. 43% of patients had previously failed to two or three biologics before starting a JAK inhibitor. We could improve patient education before starting treatment. Disclosure A. Escudero: None. S. Jain: None. N. Nisoe: None. J. McNally: None. H. Wardak: None.

rheumatology
A detailed look at the European Medicines Agency's recommendations for use of Janus kinase inhibitors in patients with atopic dermatitis

Andreas Wollenberg,Jacob P. Thyssen,Thomas Bieber,Gary Chan,Urs Kerkmann

DOI: https://doi.org/10.1111/jdv.19255

2023-06-15

Journal of the European Academy of Dermatology and Venereology

Abstract:BACKGROUND: Oral Janus kinase inhibitors (JAKi) have been approved for the treatment of several chronic inflammatory conditions, including rheumatoid arthritis (RA) and atopic dermatitis (AD). Prompted by new evidence, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) recently reassessed the benefit-risk balance of oral JAKi. The PRAC recommended that oral JAKi should be used only if no suitable alternatives are available in patients ≥65 years of age, or who have a history of atherosclerotic cardiovascular (CV) disease, other CV risk factors (e.g. history of long-term smoking) or have malignancy risk factors, and used with caution in patients at risk of pulmonary embolism or deep vein thrombosis. The European Commission's final decision was issued in March 2023.OBJECTIVES: Our goal was to highlight the PRAC recommendations, especially in the context of oral JAKi use in AD.METHODS: Authors summarized the PRAC recommendations, the new clinical evidence on oral JAKi safety and key differences between patients with RA and AD.RESULTS: Risk of developing adverse events of special interest (e.g. cardiovascular events, malignancy) is higher in patients with RA than in patients with AD, because of the higher prevalence of the underlying risk factors.CONCLUSIONS: The benefit-risk profile of JAKi approved for AD remains favourable, including use as first-line systemic therapy for patients with AD <65 years of age and without CV or malignancy risk factors.

dermatology
Waiting for JAK inhibitor safety data

Tue Wenzel Kragstrup,Bente Glintborg,Annemarie L Svensson,Christopher McMaster,Philip C Robinson,Bent Deleuran,David Fl Liew

DOI: https://doi.org/10.1136/rmdopen-2022-002236

RMD Open

Abstract:The US Food and Drug Administration (FDA) has recently added a new 'black box warning' on all currently approved Janus kinase (JAK) inhibitors indicated for the treatment of arthritis and other inflammatory conditions based on results from the ORAL Surveillance study of tofacitinib versus tumour necrosis factor alpha inhibitors in rheumatoid arthritis. This is a warning difficult to ignore because the data, being from a randomised controlled trial, are of high fidelity and hard to reproach. It is especially problematic because safety data for all the other JAK inhibitors will be pending for several years. So how might we proceed, without being bound by our stasis? The lack of absolute certainty seems to require a pragmatic approach to the routine care use of JAK inhibitors. The patients who were at greatest risk were older and had other risk factors for the corresponding adverse events, in keeping with effect modification. This highlights the need to focus on risk stratification when tailoring therapy. In this viewpoint, we propose a simple illustration to guide clinical decision-making. First, identify general risk factors for venous thromboembolic event (VTE), major adverse cardiac event (MACE) and cancer (age>65 years and smoking) and whether there is a previous history of VTE, MACE or cancer. Then, evaluate risk based on the number of other risk factors for VTE and the number of other risk factors for MACE. Ultimately, 'treat-to-target' will in the end always be 'treat-to-agreement'. As we have done in the past, and will do in the future, the optimal treatment strategy will have to be tailored based on individual patient risk factors and preferences in a shared-decision process.
Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors

Victor Yang,Tue W Kragstrup,Christopher McMaster,Pankti Reid,Namrata Singh,Stine R Haysen,Philip C Robinson,David F L Liew

DOI: https://doi.org/10.1007/s40264-023-01333-0

Abstract:Janus kinase inhibitors (JAKi) have enormous appeal as immune-modulating therapies across many chronic inflammatory diseases, but recently this promise has been overshadowed by questions regarding associated cardiovascular and cancer risk emerging from the ORAL Surveillance phase 3b/4 post-marketing requirement randomized controlled trial. In that study of patients with rheumatoid arthritis with existing cardiovascular risk, tofacitinib, the first JAKi registered for chronic inflammatory disease, failed to meet non-inferiority thresholds when compared with tumor necrosis factor inhibitors for both incident major adverse cardiovascular events and incident cancer. While this result was unexpected by many, subsequently published observational data have also supported this finding. Notably, however, such a risk has largely not yet been demonstrated in patients outside the specific clinical situation examined in the trial, even in the face of many studies examining this. Nevertheless, this signal has practically re-aligned approaches to both tofacitinib and other JAKi to varying extents, in other patient populations and contexts: within rheumatoid arthritis, but also in psoriatic arthritis, axial spondyloarthritis, inflammatory bowel disease, atopic dermatitis, and beyond. Application to individual patients can be more challenging but remains important to harness the substantive potential of JAKi to the maximum extent safely possible. This review not only explores the evolution of the regulatory response to the signal, its informing data, biological plausibility, and its impact on guidelines, but also the many factors that clinicians must consider in navigating cardiovascular and cancer risk for their patients considering JAKi as immune-modulating therapy.
Clinician and patient views on janus kinase inhibitors in the treatment of inflammatory arthritis: a mixed methods study

Savia de Souza,Ruth Williams,Elena Nikiphorou

DOI: https://doi.org/10.1186/s41927-023-00370-7

2024-01-17

BMC Rheumatology

Abstract:Abstract Background Janus kinase inhibitors (JAKi) are new targeted synthetic disease-modifying antirheumatic drugs (DMARDs) licenced in the UK to treat rheumatoid and psoriatic arthritides. Unlike currently often prescribed biological DMARDs, they target a different part of the inflammatory pathway and are taken orally. The aim of this study was to explore what UK-based rheumatology clinicians and inflammatory arthritis (IA) patients think about the awareness, prescription and use of JAKi; how they compare with biologics; and how the COVID-19 pandemic has affected how JAKi are viewed and prescribed. Methods Rheumatology clinicians and IA patients completed online surveys and participated in interviews/focus groups between September 2021 and January 2022. Survey data were analysed descriptively, and interview/focus group data underwent an inductive thematic analysis. Results 66.6% of patients had at least some awareness of JAKi, 73.0% from their rheumatology team. Problems getting earlier access to these drugs were raised by some patients, with many being prescribed JAKi after multiple other therapies had failed. 91.5% of clinicians prescribed JAKi in keeping with their local guidelines, with 72.3% prescribing them frequently as a monotherapy. Some clinicians had lingering safety concerns over JAKi use. Despite experiencing side effects and knowing of possible long-term risks, patients felt overall the benefits of JAKi outweighed the risks. 39.3% of patients were ‘very satisfied’ on JAKi, compared with 25.0% on biologics. Patients on JAKi appreciated their short half-life when it comes to infections, and their convenience as an oral therapy. When JAKi were discontinued in patients, it was predominantly due to inefficacy and non-cardiovascular adverse events. The COVID-19 pandemic resulted in increased prescription of JAKi as an alternative to injections and infusions, primarily to avoid potentially exposing patients to the coronavirus. Some patients believed their JAKi may confer some protection against developing severe COVID-19. Conclusion JAKi are an effective treatment option for IA and are liked by patients. The COVID-19 pandemic appears to have impacted their prescription favourably. However, clinicians have safety concerns over JAKi use. Any decision to go on a JAKi should be informed and take into account individual patient risk factors, circumstances and preferences.
A Practical Guide to Using Oral JAK Inhibitors for Atopic Dermatitis from the International Eczema Council

Carter Haag,Andrew Alexis,Valeria Aoki,Robert Bissonnette,Andrew Blauvelt,Raj Chovatiya,Michael J Cork,Simon G Danby,Lawrence Eichenfield,Kilian Eyerich,Melinda Gooderham,Emma Guttman-Yassky,Dirk-Jan Hijnen,Alan Irvine,Norito Katoh,Dedee F Murrell,Yael A Leshem,Adriane Levin,Ida Vittrup,Jill I Olydam,Raquel L Orfali,Amy Paller,Yael Renert-Yuval,David Rosmarin,Jonathan Silverberg,Jacob Thyssen,Sonja Ständer,Nick Stefanovic,Gail Todd,JiaDe Yu,Eric Simpson

DOI: https://doi.org/10.1093/bjd/ljae342

IF: 11.113

2024-09-10

British Journal of Dermatology

Abstract:Abstract Background Janus kinase inhibitors (JAKinibs) have the potential to dramatically alter the landscape of atopic dermatitis (AD) management due to their promising efficacy results from phase 3 trials and rapid onset of action. However, JAKinibs are not without risk, and their use is not appropriate for all AD patients, making this a medication class that dermatologists should understand and consider when treating patients with moderate-to-severe AD. Objective This consensus expert opinion statement from the International Eczema Council (IEC) provides a pragmatic approach to prescribing JAKinibs, including choosing appropriate patients, dosing, clinical and lab monitoring, as well as long-term use. Methods An international cohort of authors from the IEC with expertise in JAKinibs selected topics of interest and were formed into authorship groups covering 10 subsections. The groups performed topic-specific literature reviews, consulted up-to-date adverse event (AE) data, referred to product labels and provided analysis and expert opinion. The manuscript guidance and recommendations were reviewed by all authors as well as the IEC Research Committee. Results We recommend JAKinibs be considered for patients with moderate to severe AD seeking the benefits of rapid reduction in disease burden and itch, oral administration, and the potential for flexible dosing. Baseline risk factors should be assessed prior to prescribing JAKinibs, including increasing age, venous thromboembolisms, malignancy, cardiovascular health, kidney/liver function, pregnancy and lactation, and immunocompetence. Patients being considered for JAKinib therapy should be current on vaccinations and we provide a generalized framework for laboratory monitoring, though clinicians should consult individual product labels for recommendations as there are variations among the JAKinib class. Patients who achieve disease control should be maintained on the lowest possible dose, as many of the observed AEs occurred in a dose-dependent manner. Future studies are needed in AD patients to assess the durability and safety of continuous long-term use of JAKinibs, combination medication regimens, and the effects of flexible, episodic treatment over time. Conclusions The decision to initiate a JAKinib should be shared among patient and provider, accounting for AD severity and personal risk/benefit assessment, including consideration of baseline health risk factors, monitoring requirements and treatment costs.

dermatology
Comparison of anti-IL-6 receptor and JAK inhibitors in patients with rheumatoid arthritis from the real-world practice FIRST registry

Yusuke Miyazaki,Shingo Nakayamada,Hiroaki Tanaka,Kentaro Hanami,Shunsuke Fukuyo,Satoshi Kubo,Ippei Miyagawa,Ayako Yamaguchi,Yasuyuki Todoroki,Yoshino Inoue,Masanobu Ueno,Yoshiya Tanaka

DOI: https://doi.org/10.1093/rheumatology/keae334

2024-06-18

Rheumatology

Abstract:Abstract Objectives A molecular-targeted drug that is suitable as the second choice for patients with rheumatoid arthritis (RA) who show an inadequate response to the first biological disease-modifying antirheumatic drug (bDMARD) is unknown. This study aimed to analyse the efficacy and safety of interleukin-6 receptor (IL-6Ri) and Janus kinase inhibitors (JAKis), often selected as molecular-targeted drugs for second or subsequent treatments. Methods The efficacy and safety of JAKis and IL-6Ri were compared using propensity score-based inverse probability of treatment weighting (PS-IPTW) using propensity scores after 26 weeks of therapy in patients with RA. Results The remission rate at week 26, determined by the clinical disease activity index (CDAI), and the incidence of infection were higher in the JAKis than in the IL-6Ri group. The CDAI trajectories were divided into four according to the growth mixture modeling. IL-6Ri demonstrated greater efficacy in RA patients with ineffective to single bDMARD therapy compared with those with multiple ineffective bDMARDs. In patients who failed to respond to one bDMARD, there was no significant difference in the CDAI remission rate at week 26 between the JAKis (29.1%) and IL-6Ri (21.8%) groups (P = 0.21). However, for patients who did not respond to at least two bDMARDs, the CDAI remission rate at week 26 was higher in the JAKis than in the IL-6Ri group. Conclusions IL-6Ri offers a superior balance of efficacy and safety compared with JAKis for RA patients unresponsive to one bDMARD. However, JAKis may suit patients who do not respond to multiple bDMARDs.

rheumatology
JAK-inhibitors and risk on serious viral infection, venous thromboembolism and cardiac events in patients with rheumatoid arthritis: A protocol for a prevalent new-user cohort study using the Danish nationwide DANBIO register

Maria Luisa Faquetti,Enriqueta Vallejo-Yagüe,René Cordtz,Lene Dreyer,Andrea M Burden,Andrea M. Burden

DOI: https://doi.org/10.1371/journal.pone.0288757

IF: 3.7

2023-07-27

PLoS ONE

Abstract:Janus Kinase inhibitors (JAKis) are targeted synthetic disease-modifying antirheumatic drugs and represent an important alternative to treat patients with moderate to high rheumatoid arthritis (RA) disease activity. Safety concerns associated with increased risk for venous thromboembolism (VTE), serious viral infection, and, more recently, major adverse cardiovascular events (MACE) in JAKi users have emerged worldwide. However, as the exact mechanisms to explain these safety concerns remain unclear, the increased risk of VTE, MACE, and serious viral infection in JAKi users is heavily debated. In light of the need to enrich the safety profile of JAKis in real-world data, we aim to quantify the incidence and risk of MACE, VTE, and serious viral infections in RA patients registered in the Danish DANBIO registry, a nationwide registry of biological therapies used in rheumatology. Therefore, we will conduct a population-based cohort study using a prevalent new-user design. We will identify all RA patients in the DANBIO, ≥ 18 years old, receiving a JAKi or a tumor necrosis factor α inhibitor (TNF-αi) from January 2017 to December 2022. Prevalent and new users of JAKis will be matched to TNF-αi comparators with similar exposure history using time-conditional propensity scores (TCPS). We will describe the cumulative incidence of the outcomes (VTE, MACE, serious viral infection) in each exposure group (JAKi users; TNF-αi users), stratified by outcome type. Additionally, the Aalen-Johansen method will be used to estimate the time-to-event survival function stratified by outcome type. We will also estimate the hazard ratio (HR) with 95% confidence interval (CI) of each outcome in both exposure groups using the time-dependent Cox proportional hazards model. Results will enrich the safety profile of JAKis in real-world data.

multidisciplinary sciences
Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: a real-world study

Cristina Martinez-Molina,Ignasi Gich,Cesar Diaz-Torné,Hye S. Park,Anna Feliu,Silvia Vidal,Hèctor Corominas

DOI: https://doi.org/10.1038/s41598-023-50379-8

IF: 4.6

2024-01-03

Scientific Reports

Abstract:In real-world scenarios, Janus Kinase (JAK) inhibitors are often offered to "difficult-to-treat" rheumatoid arthritis patients, quite different from those included in randomized controlled trials. Our study aimed to evaluate the influence of patient-related factors on the effectiveness and safety of JAK inhibitors in real-world clinical practice. This observational retrospective study involved rheumatoid arthritis patients who received treatment with either tofacitinib, baricitinib, upadacitinib, or filgotinib. At 12 months of treatment, reasons for and rates of JAK inhibitor treatment discontinuation were examined. Treatment retentions were analyzed through Cox proportional hazard regression models and Kaplan–Meier estimates. Patient-related factors that could influence treatment retention were evaluated for the discontinuation reasons of lack of effectiveness and adverse events. At 12 months of treatment, discontinuation rates for 189 JAK inhibitor treatments were: lack of effectiveness (24.3%), adverse events (20.6%), and other reasons (3.7%). The remaining 51.4% represents the treatment continuation rate. No patient-related factors evaluated had an influence on treatment discontinuation due to lack of effectiveness. Ae significantly increased the risk of treatment discontinuation due to adverse events (p = 0.030). In terms of age, at 12 month of treatment, discontinuation rates due to adverse events were: < 65 years, 14.4% vs. 65 years or older, 26.3% (p = 0.019). Rheumatoid arthritis patients aged 65 years or older showed an increased risk of JAK inhibitor treatment discontinuation due to adverse events. Factors not related to treatment discontinuation were: sex, rheumatoid arthritis disease duration, rheumatoid arthritis disease activity, seropositivity for rheumatoid factor, seropositivity for anti-cyclic citrullinated peptides, number of prior biologic treatments, number of prior JAK inhibitor treatments, concomitant use of glucocorticoids, and concomitant use of conventional synthetic disease-modifying antirheumatic drugs.

multidisciplinary sciences
Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases: A Systematic Review and Meta-Analysis

Jenne P Ingrassia,Muhammad Haisum Maqsood,Joel M Gelfand,Brittany N Weber,Sripal Bangalore,Kristen I Lo Sicco,Michael S Garshick

DOI: https://doi.org/10.1001/jamadermatol.2023.4090

2024-01-01

Abstract:Importance: Janus kinase (JAK) inhibitors are an effective treatment option for patients with certain skin-related conditions, such as atopic dermatitis, alopecia areata, and vitiligo, but there is a current US Food and Drug Administration (FDA) boxed warning label for oral and topical JAK inhibitors regarding increased risk of major adverse cardiovascular events (MACE), venous thromboembolism (VTE), serious infections, malignant neoplasm, and death. However, this boxed warning was precipitated by results of the Oral Rheumatoid Arthritis Trial (ORAL) Surveillance study, which only included patients with rheumatoid arthritis, and the same association may not be observed in dermatologic conditions. Objective: To determine the risk of all-cause mortality, MACE, and VTE with JAK inhibitors in patients with dermatologic conditions. Data sources: PubMed and ClinicalTrials.gov were searched from database inception to April 1, 2023. Study selection: This review included phase 3 randomized clinical trials with a placebo/active comparator group of JAK inhibitors used for a dermatologic indication with FDA approval or pending approval or with European Union or Japanese approval. Studies without a comparison group, case reports, observational studies, and review articles were excluded. Data extraction and synthesis: This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Adverse events using odds ratios (ORs) and 95% CIs were calculated using a random-effects model and the DerSimonian-Laird method. Studies were screened, data abstracted, and quality assessed by 2 independent authors. The protocol was prospectively registered with PROSPERO. Main outcomes and measures: Primary outcomes were a composite of adjudicated MACE and all-cause mortality, and VTE. Results: The analysis included 35 randomized clinical trials with 20 651 patients (mean [SD] age, 38.5 [10.1] years; male, 54%) and a mean (SD) follow-up time of 4.9 (2.68) months. Findings did not show a significant difference between JAK inhibitors and placebo/active comparator in composite MACE and all-cause mortality (OR, 0.83; 95% CI, 0.44-1.57) or VTE (OR, 0.52; 95% CI, 0.26-1.04). Conclusions and relevance: In this systematic review and meta-analysis, use of JAK inhibitors was not associated with increased risk of all-cause mortality, MACE, and VTE compared to the placebo/active comparator groups. Additional trials with long-term follow-up are needed to better understand the safety risks of JAK inhibitors used for dermatologic indications.
JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data

Robert Harrington,Shamma Ahmad Al Nokhatha,Richard Conway

DOI: https://doi.org/10.2147/JIR.S219586

IF: 4.5

2020-09-14

Journal of Inflammation Research

Abstract:Robert Harrington, * Shamma Ahmad Al Nokhatha, * Richard Conway Department of Rheumatology, St. James's Hospital, Dublin, Ireland *These authors contributed equally to this work Correspondence: Richard Conway Department of Rheumatology, St. James's Hospital, Dublin, Ireland Email drrichardconway@gmail.com Janus kinase (JAK) Inhibitors are the latest drug class of disease-modifying medication to emerge for the treatment of rheumatoid arthritis (RA). They are a small molecule-targeted treatment and are the first oral option to compare favourably to existing biologic disease-modifying anti-rheumatic drugs (DMARDs). Tofacitinib, baricitinib and upadacitinib are the first 3 JAK inhibitors to become commercially available in the field and are the core focus of this review. To date, they have demonstrated comparable efficacy to tumour necrosis factor (TNF) inhibitors in terms of American College of Rheumatology (ACR) response rates and disease activity (DAS28) scores with similar cost to the benchmark adalimumab. This narrative review article aims to synthesise and distil the key available trial data on JAK inhibitor efficacy and safety, along with their place in the ACR and European League Against Rheumatism (EULAR) guidelines for RA. The novel mechanism of action of the JAK/STAT pathway is highlighted along with the potential effects of modulating each pathway. The rapid onset of action, role in attenuation of central pain processing and effect on structural damage and radiographic progression are also all examined in detail. We also explore the latest meta-analyses and comparative performance of each of the 3 available JAKs in an effort to determine which is most efficacious and which has the most favourable safety profile. Post marketing concerns regarding thromboembolism risk and herpes zoster infection are also discussed. Additionally, we review the cost-benefit analyses of the available JAK inhibitors and address some of the pharmacoeconomic considerations for real-world practice in the UK and US by detailing the raw acquisition cost and the value they provide in comparison to the benchmark biologic adalimumab and the anchor DMARD methotrexate. Keywords: rheumatoid arthritis, immunosuppressive therapies, JAK inhibitors, targeted synthetic DMARD, tsDMARD

immunology
Specific serum IgA-antibodies in chlamydial-induced arthritis.

H. J. Wollenhaupt,T. Krech,C. Schneider,H. Zeidler

1989-03-01

Abstract:A cohort analytic study was performed to investigate serum IgA-class antibodies against Chlamydia in 24 patients with chlamydial-induced arthritis (CIA). IgA-class antibodies against chlamydial antigens were positive (titre greater than or equal to 1:16) in 23 of the 24 IgG-positive CIA-patients (96%) in contrast to 16 of 40 patients (40%) with other rheumatic diseases (ankylosing spondylitis n = 6; undifferentiated arthritis n = 11; rheumatoid arthritis n = 12; degenerative joint disease n = 11), also positive for IgG-class chlamydial antibodies. Both the presence of specific IgA-antibodies and their geometric mean titre (1:28 vs. 1:4) differed significantly (p less than 0.001) between the two groups.
JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future

Jacopo Angelini,Rossella Talotta,Rossana Roncato,Giulia Fornasier,Giorgia Barbiero,Lisa Dal Cin,Serena Brancati,Francesco Scaglione

DOI: https://doi.org/10.3390/biom10071002

IF: 6.064

2020-07-05

Biomolecules

Abstract:Janus kinase inhibitors (JAKi) belong to a new class of oral targeted disease-modifying drugs which have recently revolutionized the therapeutic panorama of rheumatoid arthritis (RA) and other immune-mediated diseases, placing alongside or even replacing conventional and biological drugs. JAKi are characterized by a novel mechanism of action, consisting of the intracellular interruption of the JAK-STAT pathway crucially involved in the immune response. The aim of this narrative review is to globally report the most relevant pharmacological features and clinical outcomes of the developed and incoming JAKi for RA, based on the available preclinical and clinical evidence. A total of 219 papers, including narrative and systematic reviews, randomized controlled trials (RCTs), observational studies, case reports, guidelines, and drug factsheets, were selected. The efficacy and safety profile of both the first generation JAKi (baricitinib and tofacitinib) and the second generation JAKi (upadacitinib, filgotinib, peficitinib, decernotinib and itacitinib) were compared and discussed. Results from RCTs and real-life data are encouraging and outline a rapid onset of the pharmacologic effects, which are maintained during the time. Their efficacy and safety profile are comparable or superior to those of biologic agents and JAKi proved to be efficacious when given as monotherapy. Finally, the manufacturing of JAKi is relatively easier and cheaper than that of biologics, thus increasing the number of compounds being formulated and tested for clinical use.

biochemistry & molecular biology
Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis

Qige Wei,Hui Wang,Jianglin Zhao,Zhongping Luo,Chufeng Wang,Chunmei Zhu,Na Su,Shengzhao Zhang

DOI: https://doi.org/10.3389/fphar.2023.1237234

IF: 5.6

2023-08-09

Frontiers in Pharmacology

Abstract:Background: Janus kinase (JAK) inhibitors have emerged as a progressively utilized therapeutic approach for the management of rheumatoid arthritis (RA). However, the complete determination of their cardiovascular safety remains inconclusive. Hence, the primary objective of this network meta-analysis is to meticulously assess and juxtapose the cardiovascular risks linked to distinct JAK inhibitors employed in RA patients. Methods: A systematic review and network meta-analysis were meticulously conducted, encompassing a collection of randomized controlled trials (RCTs) that focused on investigating the incidence of major adverse cardiovascular events (MACE) and all-cause mortality associated with Janus kinase (JAK) inhibitors administered to patients with rheumatoid arthritis (RA). Extensive exploration was performed across multiple electronic databases, incorporating studies published until March 2023. To be included in this analysis, the RCTs were required to involve adult participants diagnosed with RA who received treatment with JAK inhibitors. To ensure accuracy, two authors independently undertook the selection of eligible RCTs and meticulously extracted aggregate data. In order to examine the outcomes of MACE and all-cause mortality, a frequentist graph theoretical approach within network meta-analyses was employed, utilizing random-effects models. Third study has been registered on PROSPERO under the reference CRD42022384611. Findings: A specific selection encompassing a total of 14 meticulously chosen randomized controlled trials was undertaken, wherein 13,524 patients were assigned randomly to distinct treatment interventions. The analysis revealed no notable disparity in the occurrence of major adverse cardiovascular events (MACE) between the interventions and the placebo group. However, in comparison to adalimumab, the employment of JAK inhibitors exhibited an association with higher rates of all-cause mortality [odds ratio (OR): 1.7, 95% confidence interval (CI): 1.02–2.81]. This observed increase in risk primarily stemmed from the usage of tofacitinib (OR: 1.9, 95% CI: 1.12–3.23). None of the other JAK inhibitors exhibited a statistically significant variance in all-cause mortality when compared to adalimumab. Interpretation: Our study suggests that JAK inhibitors may not increase the risk of MACE in RA patients but may be associated with a higher risk of all-cause mortality compared to adalimumab, primarily due to tofacitinib use. Rheumatologists should carefully consider the cardiovascular risks when prescribing JAK inhibitors, particularly tofacitinib, for RA patients. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=384611, CRD42022384611.

pharmacology & pharmacy
Proposals for the rheumatological use of JAK inhibitors

Francesco Ciccia,Roberto Caporali

DOI: https://doi.org/10.1038/s41584-023-01068-3

IF: 32.286

2024-01-13

Nature Reviews Rheumatology

Abstract:Janus kinase inhibitors have therapeutic potential for patients with immune-mediated inflammatory diseases, and evidence of greater risks of cardiovascular disease and malignancy than with TNF inhibitors should be carefully considered before recommendations against their use are made. Assessment of the risk–benefit ratios in these patients can instead guide clinical decision-making.

rheumatology
OA39 The influence of safety warnings on the prescribing of JAK inhibitors in England: an interrupted time-series analysis

Mark D Russell,Zijing Yang,Ben Walter,Edward Alveyn,Katie Bechman,Aitana Miracle,Deepak Nagra,Maryam A Adas,James B Galloway

DOI: https://doi.org/10.1093/rheumatology/keae163.039

2024-04-01

Rheumatology

Abstract:Abstract Background/Aims JAK inhibitors (JAKi) were launched in the UK for rheumatoid arthritis in 2017. Licenced indications have subsequently expanded to include other inflammatory arthritides, inflammatory bowel disease, psoriasis and atopic dermatitis. Since then, there have been numerous safety warnings from regulatory bodies, with signals for cancer, venous thromboembolism and cardiovascular events. We set out to compare how these safety warnings have influenced prescribing behaviour for individual JAKi medications in England. Methods We analysed aggregate prescribing data from all NHS hospitals in England between January 2019 and July 2023. We compared monthly prescriptions issued for individual JAKi (tofacitinib, baricitinib, upadacitinib, filgotinib) across all licenced indications. Standardisation was performed using WHO Daily Defined Doses. We conducted interrupted time-series analyses to evaluate whether changes in prescribing behaviour occurred after: i) the initial press release for the ORAL Surveillance trial data (January 2021); and ii) the European Medicines Agency (EMA) safety committee warning for the JAKi class as a whole (October 2022). Results Overall, JAKi prescribing has increased year-on-year since 2019; however, striking differences exist for individual JAKi medications. Pre-2021, an estimated additional 93 patients per month were newly initiated on tofacitinib. After the ORAL Surveillance press release (January 2021), tofacitinib initiations decreased to 26 new patients/month (p < 0.001). Following the EMA safety warning (October 2022), tofacitinib prescribing fell sharply (71 fewer patients/month; p < 0.001). A similar pattern was observed for baricitinib - pre-2021: 145 new patients/month; post-Jan 2021: 15 new patients/month; post-Oct 2022: 60 fewer patients/month (all, p < 0.001). In contrast, prescriptions for the JAK1-selective inhibitors (upadacitinib and filgotinib) have increased markedly since 2021, with no apparent impact of the pan-JAKi safety warnings. In July 2023, baricitinib remained the most prescribed JAKi in England across all indications (175,245 defined daily doses [DDD]) followed by upadacitinib (154,510 DDD), tofacitinib (105,215 DDD), and filgotinib (72,445 DDD). Conclusion Prescribing of JAKi has changed markedly in association with emerging safety warnings, with significant reductions in prescriptions for tofacitinib and baricitinib. It is notable that warnings have emerged for the JAKi class as a whole, yet prescriptions for the JAK1-selective inhibitors, upadacitinib and filgotinib, have continued to increase. Explanations could include clinicians' interpretation of risk differences within the JAKi class, as well as external pressures such as price and licenced indications. Disclosure M.D. Russell: Honoraria; AbbVie, Biogen, Eli Lilly, Galapagos, Menarini. Grants/research support; Eli Lilly, Janssen, Pfizer, UCB. Z. Yang: None. B. Walter: None. E. Alveyn: None. K. Bechman: Grants/research support; Versus Arthritis/Pfizer. A. Miracle: None. D. Nagra: None. M.A. Adas: None. J.B. Galloway: Honoraria; Abbvie, Biovitrum, BMS, Celgene, Chugai, Gilead, Janssen, Lilly, Novartis, Pfizer, Roche, Sanofi, Sobi, UCB.

rheumatology

Absence of liver tumor-initiating activity of kojic acid in mice

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician

Gammarus lacustris harboring Polymorphus paradoxus show altered patterns of serotonin-like immunoreactivity.

Creating Trust in an Acute Psychiatric Ward

P008 High response rate to Janus Kinase inhibitors after multiple biologic drug failures, across disease indications, in a District General Hospital: results from an audit of the prescribing, safety and efficacy of Janus Kinase inhibitor

A detailed look at the European Medicines Agency's recommendations for use of Janus kinase inhibitors in patients with atopic dermatitis

Waiting for JAK inhibitor safety data

Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors

Clinician and patient views on janus kinase inhibitors in the treatment of inflammatory arthritis: a mixed methods study

A Practical Guide to Using Oral JAK Inhibitors for Atopic Dermatitis from the International Eczema Council

Comparison of anti-IL-6 receptor and JAK inhibitors in patients with rheumatoid arthritis from the real-world practice FIRST registry

JAK-inhibitors and risk on serious viral infection, venous thromboembolism and cardiac events in patients with rheumatoid arthritis: A protocol for a prevalent new-user cohort study using the Danish nationwide DANBIO register

Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: a real-world study

Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases: A Systematic Review and Meta-Analysis

JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data

Specific serum IgA-antibodies in chlamydial-induced arthritis.

JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future

Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis

Proposals for the rheumatological use of JAK inhibitors

OA39 The influence of safety warnings on the prescribing of JAK inhibitors in England: an interrupted time-series analysis